SemaThera is a Montreal-based biotech developing novel anti-SEMA3A therapies for the treatment of several retinopathies. Its lead candidate, ST-102, is a bispecific biological trap that inhibits semaphorin 3A (SEMA3A) and vascular endothelial growth factor (VEGF). The company is preparing ST-102 for a clinical trial application in diabetic macular edema (DME). SemaThera closed a $2M co-investment from Senju Pharmaceutical and AmorChem and signed an exclusive option to license ST-102 in China and Japan with Senju. Under the option Senju would assume all clinical development costs and regulatory fees in China and Japan, pay milestone payments totaling in the eight-digit range, and provide a two-digit percent royalty on sales; Senju also holds exclusive rights to other indications in those territories. The company appointed John G. Clement, Ph.D., as Executive Vice‑President, Business Development, and its SEMA3A-based technologies may have future applications in cancer and neurodegenerative diseases.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2018